Methods for syntheses of organic acids from α-keto acids, including methods for syntheses of isotopically enriched organic acids from α-keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabolic flux analyses.

Methods for syntheses of organic acids from α-keto acids, including methods for syntheses of isotopically enriched organic acids from α-keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabolic flux analyses.

There is provided a method for producing a recycled material, whereby a recycled material can be efficiently obtained from a tire. The method for producing a recycled material according to the present invention includes a step of subjecting a tire to a gasification treatment to generate a gas containing a C1 gas from the tire, and a step of obtaining a recycled material containing at least one species selected from the group consisting of isoprene, butadiene, a butanediol compound, a butanol compound, a butenal compound, succinic acid, and polymers of these compounds by using the gas containing the C1 gas.

There is provided a method for producing a recycled material, whereby a recycled material can be efficiently obtained from a tire. The method for producing a recycled material according to the present invention includes a step of subjecting a tire to a gasification treatment to generate a gas containing a C1 gas from the tire, and a step of obtaining a recycled material containing at least one species selected from the group consisting of isoprene, butadiene, a butanediol compound, a butanol compound, a butenal compound, succinic acid, and polymers of these compounds by using the gas containing the C1 gas.

Crystalline forms of upadacitinib and processes for preparation thereof are disclosed. The present disclosure also relates to pharmaceutical compositions containing the upadacitinib crystalline forms, use of the upadacitinib crystalline forms for preparing JAK1 inhibitor drugs, and use of the upadacitinib crystalline forms for preparing drugs treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis. The crystalline forms of upadacitinib provided by the present disclosure have one or more improved properties compared with prior arts and have significant values for future drug optimization and development. ##STR00001##

The present invention relates to a crystal form of (−)-Cibenzoline succinate. In addition, the present invention relates to a method for preparing (−)-Cibenzoline succinate having a chiral purity of 99.9% or higher. Additionally, the present invention provides a method for preparing (−)-Cibenzoline succinate and a crystal form thereof.

The present invention relates to a crystal form of (−)-Cibenzoline succinate. In addition, the present invention relates to a method for preparing (−)-Cibenzoline succinate having a chiral purity of 99.9% or higher. Additionally, the present invention provides a method for preparing (−)-Cibenzoline succinate and a crystal form thereof.

The present invention relates generally to the field of pharmaceuticals, and specifically relates to isofagomine (IFG), novel salts thereof and preparation methods and uses of these, for example, in formulating pharmaceutical compositions for the treatment of Gaucher disease. Also provided are novel crystalline forms of isofagomine salts, methods for preparing the crystalline forms, and their use in formulating pharmaceutical compositions.

The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.

The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.